We are exploring apoptosis induced in B cell lines by antineoplastic drugs.
We suspect that induction of FAS ligand may play a role with one or more
drugs. Antibodies to FAS-L exist and an Fc fragment that inhibits binding of
FAS-L to the FAS receptor is also now available. My question is this: is it
enough to establish the FAS link by demonstrating a reduction in apoptosis
with either of these agents (the anti-FASL antibody or the Fc fragment) or is
it necessary to use both?
I appreciate any and all comments.
Thomas L. Morgan, Ph.D.
Department of Radiation Oncology
Kaiser Permanente Medical Center
4950 Sunset Blvd.
Los Angeles, CA 90027
213-667-3560
213-667-4568